FDA Gives Drug Gohibic Emergency Use Authorization to Treat COVID-19
Drug Topics
APRIL 10, 2023
The FDA granted the EUA based on the phase 3 trial results that demonstrated vilobelimab's efficacy compared to placebo, with a 23.9% relative reduction in all-cause mortality from COVID-19 at 28 days.
Let's personalize your content